Skip to Main Content

Another Massachusetts biotech is being bought by a big foreign drug company.

Belgian-based UCB said Thursday it plans to buy Ra Pharmaceuticals, a Cambridge, Mass., company that is developing treatments for rare diseases, for about $2.5 billion. UCB is paying $48 a share, more than double Ra’s closing price Wednesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED